In order to recover the costs of drug development, pharmaceutical companies must develop drugs for the global market. Problems doing so due to incompatible good clinical practice guidelines between Europe and the United States are discussed. Differences and similarities are identified and methods of facilitating compliance suggested.
BensonB.R&D investment—still a key to success?SCRIP magazine. March 1994;24–26.
2.
Food and Drug Administration, Center for Drug Evaluation and Research, Department of Health and Human Services.Guideline for the Format and Content of the Clinical and Statistical Sections of an Application. July 1998.
3.
Committee for Proprietary Medicinal Products — Good Clinical Practice Guidelines. III/3976/88, July 1991.
4.
CPMP Working Party on Efficacy of Medicinal Products of the Commission of the European Communities.Biostatistical Methodology in Clinical Trials in Applications for Marketing Authorizations for Medicinal Products. III/3630/92-EN, Draft. May 1993.
5.
MeyerGF. Acceptance of Foreign Data: An FDA Viewpoint. Appl Clin Trials. January 1994;3, (1): 55–58.
6.
U.S. FDA view — Why CTs get rejected. SCRIP. No 1542, August 22, 1990; 14.
7.
MeyerGFVinceGEKlugRR. The FDA Tapes at the First European PharmTech Conference. Pharma Tech Europe. December 1993.
8.
O'DonnellP.GCP in Europe — Controversy over Clinical Study Reports. Appl Clin Trials. December 1993;2(12):20–23.
9.
Royal Statistical Society.Statistics and Statisticians in Drug Regulation in the United Kingdom. January 1991.
